-Advisers to the U.S. Food and Drug Administration will vote whether to recommend that COVID-19 vaccines for 2024-25 should target the JN.1 variant, the most dominant this year, documents filed on Monday showed.) soared 11% in morning trade, after the documents were released. The company had said last month it would only be able to offer a COVID vaccine in the United States this autumn if regulators accept the shot it started manufacturing to target the JN.1 variant.
The documents were posted ahead of the advisers' meeting on Wednesday. The meeting was postponed from May 16 as the FDA sought more time to"obtain surveillance data and other information" on the circulating virus. Since then, the subvariant KP.2 has become the dominant strain in the U.S., estimated to account for about 28.5% of cases over a two-week period ended May 25, according to data from the U.S. Centers for Disease Control and Prevention.A variation in vaccine strain from the global norm could also pose a challenge for COVID vaccine makers, especially Novavax as it makes a more traditional protein-based shot that takes longer to manufacture.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BestLifeOnline - 🏆 533. / 51 Read more »
Source: sdut - 🏆 5. / 95 Read more »
Source: NBCNews - 🏆 10. / 86 Read more »
Source: Medscape - 🏆 386. / 55 Read more »
Source: FoxNews - 🏆 9. / 87 Read more »
Source: NPR - 🏆 96. / 63 Read more »